Isodiol International Inc (ISOLF)

[MarketProphet]

Here's an Overview $ISOLF and $TWMJF Deal that they put together several months ago. Plus Q2 the Revenue numbers which are very impressive, when compared to their market peers. $ISOLF is the most undervalued #CBD Company in the Sector IMHO. Soon it will have its day in the sun. Patience will pay off.
  

 
VANCOUVER,  /CNW/ - Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF ) (Frankfurt: LB6A.F) (the "Company" or "Isodiol") a global cannabis innovator specializing in the development of pharmaceutical and consumer products is pleased to announce it has signed a licensing agreement with Canopy Growth Corporation ("Canopy") (TSX:WEED) (https://www.canopygrowth.com). ;
Canopy Growth is the world's premier cannabis company that operates a collection of diverse brands and curated strain varieties, supported by over half a million square feet of indoor and greenhouse production capacity. Under this licensing agreement, Canopy Growth will have the right to manufacture and distribute the Company's "Pot-O-Coffee" and "Pot-O-Tea" branded marijuana infused single serve K-Cup products in Canada and certain other markets internationally as federal regulations allow.  Licensed products include caffeinated and de-caffeinated product lines as well as Isodiol's single serve "Pot-O-Coco".  In addition to the Canadian rights, Canopy Growth shall have the right of first refusal to sell the "Pot-O" brand products in any territory outside of the US, Mexico and Puerto Rico.  
"This distribution agreement has us positioned to increase our global footprint with the largest cannabis company in the world.  We will continue to develop our Pot-O-Coffee product lines with ready to drink and cold brew products while working with Canopy Growth for international distribution channels.  The Pot-O-Coffee brand is well recognized, and adding additional products to this line will continue to strengthen its market presence," stated Isodiol's CEO Marcos Agramont.
The availability of the various licensed products in Canada and elsewhere will differ depending on applicable laws and regulation.  While Canadian law does not yet permit the manufacture and sale of marijuana infused products, the Company anticipates that such products will be permitted in the near future.  Furthermore, currently proposed regulations which would permit the sale of infused products, would not allow such products to contain both marijuana and caffeine.  As such, the specific product offerings in Canada and elsewhere may be limited. The Company will provide additional updates as regulations are adopted and as product roll-out plans are developed. 
About Isodiol International Inc.
Isodiol International, Inc. is the market leader in pharmaceutical grade cannabis compounds and the industry leader in manufacturing and development of consumer products. Isodiol's nutraceutical division is the pioneer of many firsts for Hemp-derived cannabidiol (CBD), including 99% pure crystalline isolate, micro-encapsulation, and nano technology for the highest quality consumable and topical skin care products. 
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, seeking joint ventures and acquisitions to expand its portfolio of brands and subsidiaries and will aggressively continue International expansion into Latin America, Asia and Europe.
ISOL Q2 Below 

(GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and nutraceutical products, announces fiscal 2018 Q2 revenues of its wholly owned subsidiary ISO International LLC of, $4.07 million USD ($5.1 million CDN) compared to fiscal 2018 Q1 revenues of $3.92 million USD ($4.92 million CDN).
Isodiol International CEO, Marcos Agramont stated, “Over the last quarter, we have expanded our footprint in Brazil and more recently our operations into Chile.  We will continue to push our international expansion strategy by developing the European and Asian markets for our consumer products while working with local health authorities for medical approval of our flagship product, Isoderm.  We had another strong quarter of revenue growth and will continue our commitment to delivering high-quality hemp-derived CBD products through innovative delivery methods, which is the core of our success.”
For more information on Isodiol, please visit www.isodiol.com
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical and nutraceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
Join Us On Facebook: https://www.facebook.com/isodiol/
Twitter: @isodiol
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
INVESTOR RELATIONS:
[e-mail]
www.isodiol.com
MEDIA CONTACT:
Carrie Booze
North 6th Agency
212-334-9753 ext.142
[e-mail]

Read more at http://www.stockhouse.com/companies/bullboard?symbol=c.isol&postid=26941181#T5HbyE5jhxPHgPUD.99